Intelligence / Healthtech / New Clinical Trials / Boryung Biopharma Co., Ltd.
Clinicaltrial registered17 Nov 2026
Boryung Biopharma Co., Ltd.
17 Nov 2026: Trial registered · A Study to Evaluate the Efficacy and Safety of BRC-201 in Patients With Acute Uncomplicated Influenza. Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 17 Nov 2026
- Title
- A Study to Evaluate the Efficacy and Safety of BRC-201 in Patients With Acute Uncomplicated Influenza
- Conditions
- Influenza
- Phase
- Phase 3
- Study Type
- Interventional
- Status
- Recruiting
- Countries
- South Korea
- Country
- South Korea
- Reference
- NCT07943390
- Location
- South Korea
What this signal means
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS
Find the decision makers at Boryung Biopharma Co., Ltd.
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
More from South Korea
New Clinical Trials
18 NovCellinCellstrial registered · Development of an ASRS-Based Photoguide for a Clinical Trial of TRTP-101 in Adults With Atrophic ScarsClinical17 NovAstraZenecatrial registered · A Study to Investigate the Efficacy and Safety of Dato-DXd-based Combinations in Participants With TROP2 NMR+ NSCLCClinical17 NovNS Pharma, Inc.trial registered · A Global Phase 2 Extension Study of Brogidirsen in Boys With Duchenne Muscular DystrophyClinical16 NovDALIM TISSEN Co., Ltd.trial registered · Safety and Efficacy of BioSeal as a Surgical Adhesive in Cardiovascular SurgeryClinical16 NovHanmi Pharmaceutical Company Limitedtrial registered · A Study to Evaluate the Pharmacokinetics and Safety Between HIP2604 and RLD2606 in Healthy VolunteersClinical13 NovGC Biopharma Corptrial registered · Phase 2 Study of GC4006A in Healthy AdultsClinical
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.